Qingdao Haier Biomedical Co., Ltd.'s merger plan for "Blood King" has failed.
A specific plan recognized by all relevant parties could not be formed.
Due to a lack of consensus among all parties, Qingdao Haier Biomedical Co., Ltd. has pressed the termination button on the merger with Shanghai RAAS Blood Products | Read the announcement quickly.
① The reason for terminating the reorganization is that the main shareholders of the trading parties and the merging parties failed to formulate a specific plan recognized by all relevant parties; ② Shanghai RAAS Blood Products and Qingdao Haier Biomedical Co., Ltd. will resume trading on January 7 and announce a share buyback simultaneously; ③ According to informed sources, the goal of Haier Group to expand its health sector will not change.
China Resources Pharma Concludes Purchase of Controlling Stake in Boya Bio
Boya Bio-Pharmaceutical Raises $375 Million From Share Placement
Boya Bio-Pharmaceutical’s Q3 Profit Doubles as Revenue Rises 13%; Shares Jump 4%
China Resources Pharma Makes Progress on Acquisition of 30% Stake in Boya Bio